TrialScientific reports2017

Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.

Surendra K Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.